You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.


EGFR Expansion: Optimizing EGFR Identification Across the Spectrum of Non-Small Cell Lung Cancer

  • Authors: Anjali Saqi, MD, MBA; Fred Hirsch, MD, PhD; Pasi Jänne, MD, PhD
  • CME / ABIM MOC Released: 1/31/2023
  • Valid for credit through: 1/31/2024, 11:59 PM EST
Start Activity

  • Credits Available

    Physicians - maximum of 0.75 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 0.75 ABIM MOC points

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for pathologists, oncologists, pulmonologists, and other members of the multidisciplinary team (MDT) involved in the care of patients with non-small cell lung cancer (NSCLC).

The goal of this activity is for learners to be better able to accurately identify EGFR mutations in patients with NSCLC to help provide the foundation for multidisciplinary treatment strategies.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Molecular heterogeneity of EGFR mutations occurring in NSCLC
    • Methodologies used to detect EGFR mutations in NSCLC
  • Have greater competence related to
    • Accurately identifying EGFR mutations across the spectrum of NSCLC
  • Demonstrate greater confidence in their ability to
    • Implement multidisciplinary strategies for EGFR testing in patients with NSCLC


Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.


  • Anjali Saqi, MD, MBA

    Pathology and Cell Biology
    Columbia University Irving Medical Center
    New York, New York


    Anjali Saqi, MD, MBA, has the following relevant financial relationships:
    Consultant or advisor for: Bristol Myers Squibb Company; Genentech/Roche; Veracyte
    Research funding from: Boehringer Ingelheim Pharmaceuticals, Inc.; Genentech
    Other: I received honoraria/fees from the following: Dedham; Noreen Ellis Consulting; Qessential

  • Fred Hirsch, MD, PhD

    Center of Excellence for Thoracic Oncology
    Tisch Cancer Institute
    Professor of Medicine
    Icahn School of Medicine
    Mount Sinai Hospital
    New York, New York


    Fred Hirsch, MD, PhD, has no relevant financial relationships.

  • Pasi Jänne, MD, PhD

    Professor of Medicine
    Department of Medical Oncology
    Harvard Medical School
    Lowe Center for Thoracic Oncology
    Dana-Farber Cancer Institute
    Boston, Massachusetts


    Pasi Jänne, MD, PhD, has the following relevant financial relationships:
    Consultant or advisor for: AbbVie, Inc.; Accutar Biotech; Allorion Therapeutics; AstraZeneca Pharmaceuticals LP; Bayer; Biocartis; Boehringer Ingelheim Pharmaceuticals, Inc.; Chugai Pharma USA, LLC; Daiichi Sankyo, Inc.; Eisai, Inc.; Frontier Medicines; Hongyun Biotechnology; Merus; Mirati Therapeutics; Monte Rosa; Novartis Pharmaceuticals Corporation; Nuvalent; Pfizer, Inc.; Roche/Genentech; Lilly USA, LLC; Sanofi; Scorpion Therapeutics; SFJ Pharmaceuticals; Silicon Therapeutics; Syndax Pharmaceuticals, Inc.; Takeda Oncology; Transcenta; Voronoi
    Research funding from: Astellas Pharma, Inc.; AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; Lilly USA, LLC; PUMA; Revolution Medicines; Takeda Oncology
    Royalties from: LabCorp; This is for postmarketing royalties from Dana Farber Cancer Institute-owned intellectual property (I am an inventor on the patent) on EGFR mutations licensed to Lab Corp.
    Owns stock (privately owned) in: Gatekeeper Pharmaceuticals


  • Lisa Cockrell, PhD

    Medical Education Director, Medscape, LLC


    Lisa Cockrell, PhD, has no relevant financial relationships.

Compliance Reviewer

  • Lisa Simani, APRN, MS, ACNP

    Associate Director, Accreditation and Compliance, Medscape, LLC


    Lisa Simani, APRN, MS, ACNP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

Accreditation Statements


Interprofessional Continuing Education

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.


EGFR Expansion: Optimizing EGFR Identification Across the Spectrum of Non-Small Cell Lung Cancer

Authors: Anjali Saqi, MD, MBA; Fred Hirsch, MD, PhD; Pasi Jänne, MD, PhDFaculty and Disclosures

CME / ABIM MOC Released: 1/31/2023

Valid for credit through: 1/31/2024, 11:59 PM EST


Learning Feedback Questions

Please answer these questions to complement your learning experience.

  • Print